Arpit J. Vyas
#924Global Managing Director
39
Age
20y
Exp
15y
Tenure
7/10
Risk
🎓 B.Sc · Aston University, Birmingham, UK (Chemical Engineering, 2009)
🏛️ None
CompensationTBP
Personality
7
Open
6
Cons
6
Extr
5
Agre
4
Neur
Dishman Carbogen
Healthcare · Small Cap
Distressed / Turnaround · Performance-Driven
About
Arpit J. Vyas is the Global Managing Director of Dishman Carbogen, a Small Cap company in the Healthcare sector with a market cap of ₹3K Cr. A Visionary leader with 20 years of experience, he is known for intuition-driven decision-making and aggressive acquirer strategy. Pursues a global-first strategy, aggressively leveraging international R&D partnerships to position the firm in the high-end pharma outsourcing market.
FAQ
What is Arpit J. Vyas's leadership style?
Arpit J. Vyas is classified as a Visionary leader. He is intuition-driven in decision-making, with a empire expander motivation and seasonal-burst pace of execution.
What is Arpit J. Vyas's educational background?
Arpit J. Vyas holds a B.Sc from Aston University, Birmingham, UK (Chemical Engineering, 2009).
Who is the CEO of Dishman Carbogen?
Arpit J. Vyas is the Global Managing Director of Dishman Carbogen. He has been with the company for 15 years and in the current role for 5 years.
Leadership DNA
ArchetypeVisionary
MotivationEmpire Expander
CrisisRestructurer
DecisionIntuition-Driven
GrowthAggressive Acquirer
PeopleRelationship Led
InnovationFast-Follower
PaceSeasonal-Burst
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployerDemanding Machine
BrandTechnical-Expert
FocusMarket Expansion
OrientationDeep Specialist
Leadership Evidence
“Pursues a global-first strategy, aggressively leveraging international R&D partnerships to position the firm in the high-end pharma outsourcing market.”
⚡ Crisis●●●●○
He divested the Carbogen Amcis business unit to focus the group's resources and deleverage the balance sheet.
🎯 Motivation●●●●○
He has aggressively expanded the global footprint of Dishman through international acquisitions and establishing high-end manufacturing sites across Europe and Asia.
👥 People●●●○○
The company maintains a strong family-led culture with long-term stability in key management roles and promoter-led decision making.
📈 Growth●●●●●
His career is defined by the strategic acquisition of Carbogen Amcis, which transformed the company into a global contract research and manufacturing services player.
💡 Innovation●●●●○
The company operates primarily as a Contract Development and Manufacturing Organization (CDMO) that scales and executes complex chemical processes for global pharmaceutical clients rather than inventing new drug molecules.
🏃 Pace●●●○○
As a CDMO, revenue and operational intensity are dictated by the project-based nature of pharmaceutical development cycles and client-specific manufacturing timelines.
🌱 Purpose●●●●○
The company's strategic focus is heavily centered on financial recovery, debt reduction, and operational efficiency to stabilize its business model.
🏷️ Brand●●●●○
The company is recognized in the industry for its niche technical capabilities in complex chemistry and high-potency active pharmaceutical ingredients (HPAPI).
🤝 Customer●●●●●
Dishman Carbogen Amcis functions as a high-end service provider to global pharmaceutical and biotech companies, relying on long-term enterprise contracts.
💼 Employer●●●○○
The company's performance-driven culture in a highly regulated, high-pressure pharmaceutical manufacturing environment necessitates a rigorous and demanding work standard.
📋 Mandate
The company faces significant leverage challenges and margin pressure that require a focus on balance sheet stability over aggressive growth.
🏢 Culture●●●○○
Global operations in the biotechnology R&D sector necessitate a focus on scientific outcomes and high-pressure project deadlines.
Financials
Revenue FY25₹3K Cr
PAT FY25₹3 Cr
Rev CAGR 5Y8.5%
OPM5.5%
NPM0.1%
ROE0.1%
ROCE1.8%
P/E21
Fwd P/E12.7
P/B0.4
D/E40.2
Promoter69.3%
Institutional2.4%
Mkt Cap₹3K Cr
Compensation
To Be Published
Data being verified from audited reports
